GlassScriptPhysician profile
Sasha T Sutherland
NPI 1396914651
$6,874.24
in general payments reported to CMS, 2019-2025
34 companies · $1,703 in 2025
The $1,703 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $895 · 2020: $530 · 2021: $560 · 2022: $501 · 2023: $1,019 · 2024: $1,665 · 2025: $1,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,388.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,334.47 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $996.42 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $630.73 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $458.06 | 2019-2025 | |
| Amgen INC. | $396.79 | 2023-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $381.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Lucid Diagnostics INC. | $276.77 | 2023-2025 | |
| Exact Sciences Corporation | $252.46 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $237.20 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Dynavax Technologies Corporation | $230.13 | 2023-2025 | Heplisav-B |
| Abbvie INC. | $215.21 | 2019-2024 | Ubrelvy |
| Boston Scientific Corporation | $184.12 | 2025 | Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.31 | 2024-2025 | Xifaxan |
| Corcept Therapeutics | $114.75 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $114.40 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $103.85 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Gilead Sciences, INC. | $98.10 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $82.41 | 2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $78.85 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $70.15 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $60.73 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $56.01 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $54.91 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $46.18 | 2024-2025 | Contrave, Onzetra Xsail |
| Allergan, INC. | $44.25 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $39.14 | 2023-2024 | Quviviq |
| Stimwave Technologies Incorporated | $31.67 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.63 | 2021-2025 | Zoryve |
| Genentech USA, INC. | $24.40 | 2019 | |
| Shield Therapeutics INC | $22.95 | 2024 | |
| Horizon Therapeutics Plc | $22.90 | 2023 | Krystexxa |
| Dexcom, INC. | $19.70 | 2021 | |
| Vivus LLC | $18.73 | 2024 | Qsymia |
| Mylan Specialty L.P. | $15.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sasha Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.